

# Shaun G Goodman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1470050/shaun-g-goodman-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

429  
papers

27,122  
citations

77  
h-index

157  
g-index

469  
ext. papers

32,499  
ext. citations

7.3  
avg, IF

6.34  
L-index

#	Paper	IF	Citations
429	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).. <i>Heart and Vessels</i> , <b>2022</b> , 1	2.1	
428	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 417-427	15.1	2
427	ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e024156	6	2
426	Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.. <i>CJC Open</i> , <b>2022</b> , 4, 206-213	2	1
425	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users.. <i>CJC Open</i> , <b>2022</b> , 4, 180-188	2	
424	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.. <i>Advances in Therapy</i> , <b>2022</b> , 39, 1832	4.1	0
423	Objective risk assessment vs standard care for acute coronary syndromes-The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation.. <i>BMC Health Services Research</i> , <b>2022</b> , 22, 380	2.9	
422	Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.. <i>Circulation</i> , <b>2022</b> ,	16.7	2
421	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.. <i>Lancet Diabetes and Endocrinology</i> , <b>2022</b> ,	18.1	4
420	Access Denied? The Unintended Consequences of Pending Drug Pricing Rules.. <i>Current Oncology</i> , <b>2022</b> , 29, 2504-2508	2.8	0
419	Associated Factors and Clinical Outcomes in Mechanical Circulatory Support use in Patients Undergoing High Risk On-Pump Cardiac Surgery: Insights from the LEVO-CTS trial.. <i>American Heart Journal</i> , <b>2022</b> , 248, 35-35	4.9	
418	Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.. <i>American Heart Journal</i> , <b>2022</b> , 251, 1-1	4.9	1
417	Association of Cardiology Billing Amounts With Health Care Utilization and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020708	6	
416	Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469749 Adults From 2 Canadian Provinces. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e022330 <sup>6</sup>		3
415	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 304-313	16.2	11
414	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , <b>2021</b> , 44, 1219-1227	14.6	9
413	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2021</b> , 7, 222-228	4.6	

412	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , <b>2021</b> , 143, 1109-1122	16.7	16
411	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14552	3.5	2
410	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e006646	5.8	4
409	Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y <sub>12</sub> Inhibitor Therapy: A Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 739-750	5	29
408	Contemporary use of guideline-based higher potency P2Y <sub>12</sub> receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 839-847	3.3	2
407	Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2021</b> , 152, 49-56	3	2
406	An Association Between Cardiologist Billing Patterns, Health Care Use, and Outcomes in Cardiac Patients. <i>CJC Open</i> , <b>2021</b> , 3, 758-768	2	
405	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From the CONNECT AF+PCI Study. <i>CJC Open</i> , <b>2021</b> , 3, 1419-1427	2	0
404	Early invasive coronary angiography and acute ischaemic heart failure outcomes. <i>European Heart Journal</i> , <b>2021</b> , 42, 3756-3766	9.5	3
403	Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14597	2.9	0
402	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 549-559	3.9	3
401	Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. <i>American Heart Journal</i> , <b>2021</b> , 232, 84-93	4.9	7
400	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , <b>2021</b> , 231, 18-24	4.9	4
399	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 33-43	3.9	10
398	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , <b>2021</b> , 231, 121-127	4.9	16
397	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13861	2.9	1
396	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. <i>American Journal of Cardiology</i> , <b>2021</b> , 140, 62-68	3	7
395	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 39-49	27.4	22

394	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , <b>2021</b> , 143, 583-596	16.7	31
393	Treatment Inertia in Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020126	6	2
392	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study.. <i>CJC Open</i> , <b>2021</b> , 3, 1463-1470	2	
391	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1837-1845	3.8	1
390	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , <b>2021</b> , 144, 1295-1307	16.7	13
389	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 421-433	15.1	13
388	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107997	3.2	
387	Factors associated with actively working in the very long-term following acute coronary syndrome. <i>Clinics</i> , <b>2021</b> , 76, e2553	2.3	
386	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e007903	5.8	0
385	Alirocumab after acute coronary syndrome in patients with a history of heart failure.. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	4
384	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , e023143	6	
383	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 1352-1361	3.3	1
382	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2297-2308	15.1	23
381	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 418-435	18.1	59
380	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , <b>2020</b> , 2, 49-54	2	2
379	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1395-1407	59.2	642
378	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. <i>Circulation</i> , <b>2020</b> , 141, 1608-1617	16.7	52
377	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. <i>Circulation</i> , <b>2020</b> , 141, 1618-1627	16.7	48

376	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 162-171	15.1	17
375	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , <b>2020</b> , 311, 7-14	3.2	4
374	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 448-451	15.1	4
373	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , <b>2020</b> , 2, 402-415	2	0
372	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design. <i>JACC: CardioOncology</i> , <b>2020</b> , 2, 70-81	3.8	15
371	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. <i>CJC Open</i> , <b>2020</b> , 2, 118-128	2	4
370	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 24-32	3.3	6
369	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , <b>2020</b> , 141, 781-783	16.7	48
368	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 133-144	15.1	147
367	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , <b>2020</b> , 41, 2248-2258	9.5	29
366	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 446-452	14.6	31
365	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 65-74	7	7
364	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 4245-4255	9.5	44
363	Cardiac Stress Testing After Coronary Revascularization. <i>American Journal of Cardiology</i> , <b>2020</b> , 136, 9-14	3	1
362	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 435-450	15.1	5
361	Optimizing screening and management of cardiovascular health in prostate cancer: A review. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E458-E464	1.2	1
360	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , <b>2020</b> , 142, 2231-2239	16.7	15
359	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , <b>2020</b> , 74, e13625	2.9	2

358	Relation of High Lipoprotein(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4568-4584	4.1	4
357	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 761-771	27.4	107
356	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 4114-4123	9.5	12
355	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. <i>European Heart Journal</i> , <b>2020</b> , 41, 86-94	9.5	45
354	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Registry in Acute Coronary SyndromEs). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2020</b> , 6, 284-292	4.6	3
353	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2020</b> , 159, 2302-2309.e6	1.5	21
352	Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1160-1169	16.2	12
351	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Circulation</i> , <b>2019</b> , 140, 1693-1702	16.7	205
350	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1177-1186	15.1	33
349	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , <b>2019</b> , 140, 1578-1589	16.7	24
348	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , <b>2019</b> , 140, 1921-1932	16.7	40
347	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , <b>2019</b> , 140, 1960-1963	16.7	6
346	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 2801-2809	9.5	27
345	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2819-2828	15.1	34
344	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , <b>2019</b> , 140, 103-112	16.7	72
343	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007811	6	60
342	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1509-1524	59.2	538
341	Living alone and cardiovascular disease outcomes. <i>Heart</i> , <b>2019</b> , 105, 1087-1095	5.1	10

340	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 160-168	3.8	3
339	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 273-286	16.2	65
338	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1167-1176	15.1	87
337	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , <b>2019</b> , 215, 106-113	4.9	5
336	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 618-628	18.1	120
335	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005858	5.8	13
334	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , <b>2019</b> , 140, 2054-2062	16.7	41
333	Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 653-660	3.8	23
332	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , <b>2019</b> , 9, e032165	3	12
331	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. <i>Pharmacogenetics and Genomics</i> , <b>2019</b> , 29, 76-83	1.9	5
330	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e008018	6	15
329	Short term outcome following acute phase switch among P2Y inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. <i>IJC Heart and Vasculature</i> , <b>2019</b> , 22, 39-45	2.4	5
328	Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 430-437	3.8	3
327	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , <b>2019</b> , 19, 173-183	4	15
326	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 93, E369-E377	2.7	3
325	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 387-396	15.1	96
324	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 208-217	4.3	11
323	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 309-317	4.3	4

322	Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 225-233	5.1	6
321	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , <b>2018</b> , 257, 78-83	3.2	7
320	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 89-96	4.9	10
319	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. <i>Coronary Artery Disease</i> , <b>2018</b> , 29, 469-476	1.4	3
318	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). <i>Clinical Cardiology</i> , <b>2018</b> , 41, 285-292	3.3	5
317	Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. <i>American Heart Journal</i> , <b>2018</b> , 200, 96-101	4.9	74
316	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 736-743	3.8	5
315	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2018</b> , 4, 309-317	4.6	7
314	An open-Label, 2x2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , <b>2018</b> , 200, 17-23	4.9	56
313	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 391-399	16.2	49
312	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , <b>2018</b> , 42, 130-137	2.1	8
311	Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 31-37	3.8	4
310	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , <b>2018</b> , 197, 1-8	4.9	5
309	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. <i>Circulation</i> , <b>2018</b> , 138, 527-536	16.7	164
308	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1350-1361	3.8	2
307	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. <i>American Heart Journal</i> , <b>2018</b> , 196, 56-64	4.9	6
306	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 294-300	3	4
305	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2097-2107	59.2	1277



304	Association of Anemia With Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e007175	6	15
303	Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e010394	6	13
302	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009304	6	12
301	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 1519-1529	40	771
300	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009859	6	26
299	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , <b>2018</b> , 39, 3798-3806	9.5	42
298	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 97-103	4.9	23
297	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 944-951 <sup>3</sup>		7
296	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 166-169	3.8	10
295	Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 119-127	15.1	33
294	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	35
293	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical manaGement and healthcare Resource utilization of stable coronary artery diSease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , <b>2017</b> , 236, 54-60	3.2	19
292	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 940-942	3.8	4
291	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2017</b> , 240, 30-36	3.2	11
290	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1933-1942	59.2	406
289	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 1214-1226 <sup>5</sup>		8
288	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , <b>2017</b> , 190, 135-139	4.9	21
287	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2017</b> , 3, 214-220	6.4	0

286	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care of Patients With Atrial Fibrillation (CONNECT AF). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 153-159	3	6
285	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 153	15.1	2
284	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2032-2042	59.2	156
283	Association between gender and short-term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. <i>BMJ Open</i> , <b>2017</b> , 7, e015241	3	12
282	Population-Based Study on Patterns of Cardiac Stress Testing After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2017</b> , 10,	5.8	6
281	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. <i>American Heart Journal</i> , <b>2017</b> , 192, 105-112	4.9	26
280	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. <i>American Heart Journal</i> , <b>2017</b> , 193, 46-54	4.9	1
279	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2017</b> , 244, 24-29	3.2	10
278	Stress testing after percutaneous coronary interventions: a population-based study. <i>CMAJ Open</i> , <b>2017</b> , 5, E417-E423	2.5	5
277	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 366-377	3.8	19
276	Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. <i>International Journal of Cardiology</i> , <b>2017</b> , 228, 459-464	3.2	9
275	Rationale and design of the long-Term risk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dIsease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 1197-1204	3.3	7
274	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. <i>EuroIntervention</i> , <b>2017</b> , 13, 69-77	3.1	13
273	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2017</b> , 3, 222-231	4.6	4
272	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1073-82	27.4	65
271	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LVS-STE) trial. <i>Perfusion</i> , <b>2017</b> , 32, 10-17	4.9	20
270	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. <i>Circulation: Cardiovascular Interventions</i> , <b>2016</b> , 9,	6	73
269	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 754-9	3	12

268	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , <b>2016</b> , 13, 140-8	2.2	12
267	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 214-22	4.3	9
266	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1289-97	15.1	13
265	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1221.e11-1221.e18	3.8	5
264	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-HII Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 646-56	5	25
263	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 336-43	3.8	11
262	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. <i>Cardiovascular Revascularization Medicine</i> , <b>2016</b> , 17, 295-301	1.6	2
261	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , <b>2016</b> , 218, 291-297	3.2	5
260	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, S15-34	3.8	7
259	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , <b>2016</b> , 102, 1396-402	5.1	10
258	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. <i>International Journal of Cardiology</i> , <b>2016</b> , 222, 86-92	3.2	3
257	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sStudy. <i>American Heart Journal</i> , <b>2016</b> , 180, 82-9	4.9	17
256	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sStudy (COAPT). <i>American Heart Journal</i> , <b>2015</b> , 181, 21-31	4.9	16
255	Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <i>Journal of Invasive Cardiology</i> , <b>2016</b> , 28, E203-E210	0.7	4
254	Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1005-12	3	3
253	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , <b>2015</b> , 169, 743-50	4.9	14
252	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1455-61	3.8	21
251	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , <b>2015</b> , 101, 1475-84	5.1	10

250	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. <i>Heart</i> , <b>2015</b> , 101, 1554-61	5.1	7
249	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , <b>2015</b> , 190, 34-9	3.2	12
248	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 766-75	2.4	58
247	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 777-787	15.1	31
246	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> <b>2015</b> , 170, 683-694.e3	4.9	22
245	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , <b>2015</b> , 170, 995-1004.e1	4.9	18
244	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , <b>2015</b> , 36, 976-83	9.5	42
243	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 493	3.2	2
242	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 499-508	4.3	59
241	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , <b>2015</b> , 36, 385-92a	9.5	28
240	Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 641-6	3	13
239	Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 9, 166-174	5	27
238	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1873-80	9.5	126
237	Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 132-7	3.8	6
236	Prognostic implications of prominent R wave in electrocardiographic leads V1 or V2 in patients with acute coronary syndrome. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1962-7	3	
235	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 2516-23	9.5	65
234	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 891-900	15.1	172
233	Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1725-31	3.8	20

232	Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. <i>American Heart Journal</i> , <b>2014</b> , 168, 757-65	4.9	4
231	Prehospital ticagrelor in ST-segment elevation myocardial infarction. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1016-27	59.2	409
230	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 233-41	9.5	67
229	Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 955-61	3	9
228	Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. <i>ClinicoEconomics and Outcomes Research</i> , <b>2014</b> , 6, 49-62	1.7	10
227	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , <b>2014</b> , 100, 1456-61	5.1	2
226	Efficacy of an early invasive strategy after fibrinolysis in ST-elevation myocardial infarction relative to the extent of coronary artery disease. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1555-61	3.8	2
225	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. <i>American Heart Journal</i> , <b>2014</b> , 168, 682-9	4.9	303
224	Targeted temperature management processes and outcomes after out-of-hospital cardiac arrest: an observational cohort study*. <i>Critical Care Medicine</i> , <b>2014</b> , 42, 2565-74	1.4	20
223	Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , <b>2014</b> , 168, 189-96.e1	4.9	13
222	Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 202-7	3	18
221	Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: a follow-up study. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1586-92	3.8	4
220	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2013</b> , 2, 350-8	4.3	21
219	Use and timing of coronary angiography and associated in-hospital outcomes in Canadian non-ST-segment elevation myocardial infarction patients: insights from the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1429-35	3.8	18
218	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2013</b> , 166, 290-7	4.9	13
217	Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 544-51	3	3
216	Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 1461-3	15.1	1
215	Temporal trends and referral factors for cardiac rehabilitation post-acute coronary syndrome in Ontario: insights from the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1604-9	3.8	8

214	Canada Acute Coronary Syndrome Risk Score: a new risk score for early prognostication in acute coronary syndromes. <i>American Heart Journal</i> , <b>2013</b> , 166, 58-63	4.9	41
213	Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. <i>American Heart Journal</i> , <b>2013</b> , 166, 716-22	4.9	18
212	Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 960-8	3.8	15
211	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery (ATLANTIC) study. <i>American Heart Journal</i> , <b>2013</b> , 166, 100-107	4.9	39
210	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 2720-5	3.2	3
209	Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. <i>European Heart Journal</i> , <b>2013</b> , 34, 903-8	9.5	21
208	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. <i>Coronary Artery Disease</i> , <b>2013</b> , 24, 321-7	1.4	2
207	Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. <i>Circulation</i> , <b>2013</b> , 128, 823-33	16.7	103
206	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 1785-94	27.4	176
205	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: a subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , <b>2012</b> , 164, 343-50	4.9	6
204	Response to Letter Regarding Article, Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO. <i>Circulation</i> , <b>2012</b> , 126,	16.7	1
203	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 12-20	7	6
202	Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. <i>Circulation</i> , <b>2012</b> , 125, 978-86	16.7	139
201	Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2012</b> , 163, 66-73	4.9	138
200	Cardiogenic shock complicating acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , <b>2012</b> , 163, 963-71	4.9	81
199	The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 48-53	3.8	7
198	Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 40-7	3.8	14
197	Management and outcome of acute coronary syndrome patients in relation to prior history of atrial fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 443-9	3.8	18

196	Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 114-9	5.1	2
195	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 36-43	5.1	14
194	Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 332-6	3	3
193	Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients (from the Canadian GRACE Experience). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1418-24	3	9
192	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1297-309	59.2	631
191	Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. <i>Heart Asia</i> , <b>2012</b> , 4, 137-40	1.9	2
190	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 699-708	59.2	765
189	Has the CLOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early $\beta$ -blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , <b>2011</b> , 161, 291-7	4.9	5
188	Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 138-45	3.8	5
187	Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 711-5	3.8	9
186	Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 756-62	3.8	10
185	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2011</b> , 161, 878-85	4.9	6
184	Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 617-24	3	42
183	The impact of postrandomization crossover of therapy in acute coronary syndromes care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2011</b> , 4, 211-9	5.8	3
182	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin Acute Coronary Syndromes Trial. <i>Circulation</i> , <b>2011</b> , 123, 1843-53	16.7	130
181	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>European Heart Journal</i> , <b>2011</b> , 32, 1994-2002	9.5	26
180	Factors influencing underutilization of evidence-based therapies in women. <i>European Heart Journal</i> , <b>2011</b> , 32, 1337-44	9.5	134
179	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , <b>2011</b> , 32, 2256-65	9.5	34

178	Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada. <i>Value in Health</i> , <b>2010</b> , 13, 915-21	3.3	44
177	Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1841-7	27.4	213
176	Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 530-7	5.8	52
175	Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). <i>Diabetes Care</i> , <b>2010</b> , 33, 2558-60	14.6	7
174	Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. <i>European Heart Journal</i> , <b>2010</b> , 31, 2156-69	9.5	129
173	Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , <b>2010</b> , 31, 958-66	9.5	8
172	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. <i>European Heart Journal</i> , <b>2010</b> , 31, 1328-36	9.5	39
171	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. <i>European Heart Journal</i> , <b>2010</b> , 31, 667-75	9.5	53
170	Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. <i>International Journal of Cardiology</i> , <b>2010</b> , 139, 123-33	3.2	32
169	Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. <i>International Journal of Cardiology</i> , <b>2010</b> , 144, 36-41	3.2	20
168	Recurrent ischemia across the spectrum of acute coronary syndromes: prevalence and prognostic significance of (re-)infarction and ST-segment changes in a large contemporary registry. <i>International Journal of Cardiology</i> , <b>2010</b> , 145, 15-20	3.2	11
167	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. <i>American Heart Journal</i> , <b>2010</b> , 159, 40-6	4.9	22
166	Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. <i>American Heart Journal</i> , <b>2010</b> , 159, 354-60	4.9	70
165	QRS prolongation in patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2010</b> , 159, 593-8	4.9	16
164	Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. <i>American Heart Journal</i> , <b>2010</b> , 159, 605-11	4.9	9
163	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2010</b> , 160, 420-7	4.9	22
162	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , <b>2010</b> , 160, 855-61	4.9	20
161	Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. <i>Canadian Journal of Cardiology</i> , <b>2010</b> , 26, 129-34	3.8	36



160	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , <b>2010</b> , 26, 297-302	3.8	77
159	Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). <i>Canadian Journal of Cardiology</i> , <b>2010</b> , 26, e330-5	3.8	40
158	Disparities in management patterns and outcomes of patients with non-ST-elevation acute coronary syndrome with and without a history of cerebrovascular disease. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 1083-9	3	22
157	Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1270-6	3	29
156	Comparison of baseline characteristics, management and outcome of patients with non-ST-segment elevation acute coronary syndrome in versus not in clinical trials. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1389-96	3	29
155	Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1417-22	3	29
154	Does enoxaparin have enough FINESSE to replace unfractionated heparin in primary percutaneous coronary intervention?. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 213-4	5	
153	Intravenous platelet blockade with cangrelor during PCI. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2330-41	59.2	480
152	Platelet inhibition with cangrelor in patients undergoing PCI. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2318-29	59.2	454
151	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. <i>Circulation</i> , <b>2009</b> , 119, 2877-85	16.7	371
150	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. <i>European Heart Journal</i> , <b>2009</b> , 30, 549-57	9.5	65
149	Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?. <i>Stroke</i> , <b>2009</b> , 40, 1417-24	6.7	53
148	G-protein-coupled receptors as signaling targets for antiplatelet therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 449-57	9.4	90
147	ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 154-8	3	3
146	Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1530-6	3	56
145	Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 1330-5	3	2
144	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an EXTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 27, 11-7	5.1	19
143	Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. <i>American Heart Journal</i> , <b>2009</b> , 157, 642-50.e1	4.9	27

142	Pulmonary artery catheterization in patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2009</b> , 158, 170-6	4.9	6
141	The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2009</b> , 158, 193-201.e1-5	4.9	145
140	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. <i>American Heart Journal</i> , <b>2009</b> , 158, 392-9	4.9	123
139	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. <i>American Heart Journal</i> , <b>2009</b> , 158, 917-24	4.9	15
138	Predictors and implications of Q-waves in ST-elevation acute coronary syndromes. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 144-51	2.4	9
137	Unprotected left main revascularization in patients with acute coronary syndromes. <i>European Heart Journal</i> , <b>2009</b> , 30, 2308-17	9.5	92
136	Routine early angioplasty after fibrinolysis for acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2705-18	59.2	376
135	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. <i>Canadian Journal of Cardiology</i> , <b>2009</b> , 25, e370-6	3.8	29
134	Outcome of patients with acute coronary syndromes enrolled in clinical trials. <i>Coronary Artery Disease</i> , <b>2009</b> , 20, 473-6	1.4	1
133	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , <b>2009</b> , 30, 321-9	9.5	99
132	Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. <i>PLoS ONE</i> , <b>2009</b> , 4, e7947	3.7	90
131	Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 919-24	3	11
130	Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 1142-5	3	22
129	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , <b>2008</b> , 29, 609-17	9.5	195
128	Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , <b>2008</b> , 129, 233-7	3.2	3
127	Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , <b>2008</b> , 155, 19-25	4.9	34
126	Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2008</b> , 155, 718-24	4.9	7
125	Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , <b>2008</b> , 156, 177-84	4.9	3

124	Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. <i>American Heart Journal</i> , <b>2008</b> , 156, 248-55	4.9	52
123	Impact of delayed presentation on management and outcome of non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2008</b> , 156, 262-8	4.9	6
122	Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. <i>American Heart Journal</i> , <b>2008</b> , 156, 769-75	4.9	16
121	Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2008</b> , 156, 797-803	4.9	6
120	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. <i>Canadian Journal of Cardiology</i> , <b>2008</b> , 24, 363-8	3.8	5
119	Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>Canadian Journal of Cardiology</i> , <b>2008</b> , 24, 705-8 <sup>8</sup>	3.8	8
118	Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. <i>European Heart Journal</i> , <b>2008</b> , 29, 871-9	9.5	25
117	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2008</b> , 5, 580-9		51
116	Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 708S-775S	5.3	88
115	Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 670S-707S	5.3	123
114	Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. <i>Journal of General Internal Medicine</i> , <b>2008</b> , 23, 310-6	4	37
113	Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. <i>European Heart Journal</i> , <b>2008</b> , 29, 31-7	9.5	8
112	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. <i>Catheterization and Cardiovascular Interventions</i> , <b>2007</b> , 69, 73-83	2.7	88
111	Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 186-8	3	2
110	Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 169-74	3	16
109	Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein $\geq 100$ mg/dl versus. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 913-8	3	22
108	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. <i>European Heart Journal</i> , <b>2007</b> , 28, 1072-8	9.5	197
107	Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. <i>European Heart Journal</i> , <b>2007</b> , 28, 1079-84	9.5	11

106	Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. <i>Circulation</i> , <b>2007</b> , 116, 2669-77	16.7	37
105	Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1892-900	27.4	624
104	Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. <i>Circulation</i> , <b>2007</b> , 116, 2793-801	16.7	182
103	Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 1009-16		118
102	Are acute coronary syndromes risk models too complex? reply. <i>European Heart Journal</i> , <b>2007</b> , 28, 2176-2177		17
101	Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. <i>American Heart Journal</i> , <b>2007</b> , 153, 493-9	4.9	14
100	Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. <i>American Heart Journal</i> , <b>2007</b> , 153, 500-6	4.9	19
99	Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , <b>2007</b> , 153, 960-9	4.9	18
98	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , <b>2007</b> , 154, 71-8	4.9	71
97	Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. <i>American Heart Journal</i> , <b>2007</b> , 154, 1108-15	4.9	126
96	Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. <i>Canadian Journal of Cardiology</i> , <b>2007</b> , 23, 1073-9	3.8	30
95	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. <i>Canadian Journal of Cardiology</i> , <b>2007</b> , 23, 1124-30	3.8	24
94	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , <b>2007</b> , 28, 2077-86	9.5	143
93	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , <b>2007</b> , 28, 1717-22	9.5	103
92	Prognostic significance of admission heart failure in patients with non-ST-elevation acute coronary syndromes (from the Canadian Acute Coronary Syndrome Registries). <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 470-3	3	29
91	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). <i>BMJ, The</i> , <b>2006</b> , 333, 1091	5.9	941
90	Bedtime administration of graded-release diltiazem in patients with inadequate BP control: a tolerability and efficacy study. <i>American Journal of Cardiovascular Drugs</i> , <b>2006</b> , 6, 393-400	4	1
89	Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 115-20	3.8	32

88	Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 835-9	3.8	9
87	Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 663-77	3.8	9
86	Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 1121-6	3.8	14
85	Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. <i>Journal of Vascular Surgery</i> , <b>2006</b> , 44, 776-81	3.5	15
84	A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 1346-54	15.1	69
83	Contemporary management of dyslipidemia in high-risk patients: targets still not met. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 676-83	2.4	133
82	Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. <i>American Heart Journal</i> , <b>2006</b> , 151, 10-5	4.9	40
81	Age-related differences in the management and outcome of patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2006</b> , 151, 352-9	4.9	79
80	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized	4.9	28
79	Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , <b>2006</b> , 151, 654-60	4.9	88
78	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , <b>2006</b> , 151, 654-60	4.9	88
78	The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. <i>American Heart Journal</i> , <b>2006</b> , 151, 791-7	4.9	6
77	The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: current status in an era of revascularization and reperfusion. <i>American Heart Journal</i> , <b>2006</b> , 152, 11-8	4.9	47
76	ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. <i>American Heart Journal</i> , <b>2006</b> , 152, 270-6	4.9	20
75	The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. <i>American Heart Journal</i> , <b>2006</b> , 152, 277-84	4.9	8
74	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2006</b> , 152, 676-83	4.9	37
73	Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 21, 211-20	5.1	12
72	A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. <i>European Heart Journal</i> , <b>2005</b> , 26, 1726-33	9.5	10
71	Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. <i>American Heart Journal</i> , <b>2005</b> , 149, 275-83	4.9	15

70	Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. <i>American Heart Journal</i> , <b>2005</b> , 150, 659-65	4.9	17
69	Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. <i>American Heart Journal</i> , <b>2005</b> , 150, 690-4	4.9	91
68	Management of risk in peripheral artery disease: recent therapeutic advances. <i>American Heart Journal</i> , <b>2005</b> , 150, 35-40	4.9	21
67	Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. <i>American Heart Journal</i> , <b>2005</b> , 149, S73-80	4.9	6
66	In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 913-6	3	95
65	Short- and long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 1050-2	3	6
64	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. <i>Catheterization and Cardiovascular Interventions</i> , <b>2005</b> , 66, 149-57	2.7	13
63	High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 2594-600	27.4	50
62	Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. <i>Canadian Journal of Cardiology</i> , <b>2005</b> , 21, 85-90	3.8	3
61	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. <i>Canadian Journal of Cardiology</i> , <b>2005</b> , 21, 501-7	3.8	1
60	Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. <i>European Heart Journal</i> , <b>2004</b> , 25, 2006-12	9.5	18
59	Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 89-96	27.4	217
58	Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 45-54	27.4	570
57	A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 2727-33	27.4	1064
56	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 288-93	3	138
55	One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 25-9	3	82
54	Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 38-43	15.1	89
53	Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , <b>2004</b> , 147, 42-8	4.9	77

52	Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome. <i>American Heart Journal</i> , <b>2004</b> , 148, 1020-7	4.9	73
51	Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. <i>American Heart Journal</i> , <b>2004</b> , 148, 269-76	4.9	7
50	How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. <i>American Heart Journal</i> , <b>2004</b> , 148, 1028-33	4.9	16
49	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 73-81	2.4	176
48	Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. <i>Chest</i> , <b>2004</b> , 126, 461-9	5.3	342
47	Low-molecular-weight heparins in ischemic heart disease. <i>Current Opinion in Cardiology</i> , <b>2004</b> , 19, 309-16	1	5
46	Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. <i>Circulation</i> , <b>2003</b> , 107, 238-44	16.7	182
45	The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. <i>European Heart Journal</i> , <b>2003</b> , 24, 1024-34	9.5	9
44	ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. <i>European Heart Journal</i> , <b>2003</b> , 24, 1515-22	9.5	19
43	Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular disease. <i>Atherosclerosis</i> , <b>2003</b> , 171, 255-8	3.1	15
42	Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. <i>American Heart Journal</i> , <b>2003</b> , 146, 33-41	4.9	154
41	Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. <i>American Heart Journal</i> , <b>2003</b> , 146, 640-5	4.9	9
40	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , <b>2003</b> , 146, 999-1006	4.9	83
39	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , <b>2003</b> , 24, 1414-24	9.5	173
38	Predictors of hospital mortality in the global registry of acute coronary events. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 2345-53		1414
37	The development of Partners for Health's integrated community pathway for postmyocardial infarction patients. <i>Canadian Journal of Cardiology</i> , <b>2003</b> , 19, 231-5	3.8	1
36	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 791-6	3	235
35	Enoxaparin treatment in unstable coronary artery disease: international cost savings. <i>Chest</i> , <b>2002</b> , 121, 666-7	5.3	

34	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). <i>Lancet, The</i> , <b>2002</b> , 359, 373-7	4.0	423
33	Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. <i>American Heart Journal</i> , <b>2002</b> , 144, 60-7	4.9	16
32	Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. <i>American Heart Journal</i> , <b>2002</b> , 144, 243-250	4.9	20
31	An early invasive strategy reduced the incidence of major cardiac events in patients with unstable coronary syndromes. <i>ACP Journal Club</i> , <b>2002</b> , 136, 4		
30	Review: oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. <i>ACP Journal Club</i> , <b>2002</b> , 137, 85		
29	Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , <b>2002</b> , 18, 1179-90	3.8	2
28	Review: Oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. <i>ACP Journal Club</i> , <b>2002</b> , 137, 85		
27	Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction. <i>Journal of Nuclear Cardiology</i> , <b>2001</b> , 8, 136-43	2.1	16
26	Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 842-7	3	27
25	Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. <i>Circulation</i> , <b>2001</b> , 104, 2653-9	16.7	86
24	Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. <i>Circulation</i> , <b>2001</b> , 103, 954-60	16.7	26
23	Standards for the function of an academic 12-lead electrocardiographic core laboratory. <i>Journal of Electrocardiology</i> , <b>2001</b> , 34, 41-7	1.4	6
22	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 64-71	15.1	119
21	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 24-9	3	5
20	Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. <i>American Heart Journal</i> , <b>2000</b> , 139, 423-9	4.9	50
19	Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. <i>American Heart Journal</i> , <b>2000</b> , 139, 962-70	4.9	24
18	Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. <i>American Heart Journal</i> , <b>2000</b> , 140, 385-94	4.9	19
17	Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 688-9	15.1	130



16	Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 1507-13	15.1	50
15	Exertional sudden coronary death was associated with acute plaque rupture in men. <i>Evidence-based Cardiovascular Medicine</i> , <b>1999</b> , 3, 61		
14	Women had a worse prognosis than men after myocardial infarction. <i>ACP Journal Club</i> , <b>1999</b> , 130, 46		
13	Abciximab and heparin given during coronary interventions reduced combined death, MI, and urgent revascularization. <i>ACP Journal Club</i> , <b>1999</b> , 131, 40		
12	Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. <i>American Journal of Cardiology</i> , <b>1998</b> , 82, 19L-24L	3	85
11	Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 1070-7	3	22
10	Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. <i>Circulation</i> , <b>1998</b> , 97, 444-50	16.7	63
9	A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 447-52	59.2	1192
8	Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 29, 770-7	15.1	37
7	Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators). <i>Journal of the American College of Cardiology</i> , <b>1996</b> , 27, 1327-32	15.1	62
6	Women with acute myocardial infarction had worse prognosis than men. <i>ACP Journal Club</i> , <b>1996</b> , 125, 43		
5	Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol. <i>Clinical Cardiology</i> , <b>1995</b> , 18, 653-8	3.3	8
4	Coronary angiography in Q-wave versus non-Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>1995</b> , 76, 429-30	3	1
3	Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. <i>American Journal of Cardiology</i> , <b>1994</b> , 74, 657-61	3	18
2	Does ambulatory monitoring contribute to exercise testing and myocardial perfusion scintigraphy in the prediction of the extent of coronary artery disease in stable angina?. <i>American Journal of Cardiology</i> , <b>1994</b> , 73, 747-52	3	8
1	Acute coronary thrombotic occlusion following exercise testing 6 weeks after percutaneous transluminal coronary angioplasty. <i>Catheterization and Cardiovascular Diagnosis</i> , <b>1992</b> , 27, 40-4		6